Skip to main content
Vidac Pharma
T9G

Investor Relations

Vidac Pharma Holdings PLC — listed on Xetra, Tradegate, Hamburg, Stuttgart and Düsseldorf

Stock Information

Data provided by TradingView. Exchange: XETRA | Ticker: T9G

Key Share Information

Symbol
T9G
ISIN
GB00BM9XQ619
WKN
A3DTUQ
LEI
875500BCH1T6XX5EUG13
Exchanges
Hamburg · Stuttgart · Düsseldorf
Trading Venues
Xetra · Tradegate

Investment Overview

  • ✦USD 22.8M invested by private investors since 2012
  • ✦USD 4.9M invested by CSO and Innovation Authorities
  • ✦Listed on three German exchanges under BaFin authorisation
  • ✦Winner of the Seal of Excellence from Horizon Europe EIC
  • ✦Management buyout by Herzberg and Richter in 2019
  • ✦Company funded by shareholder and management investments since 2019

Financial Calendar

Past Events(26)

Show
2026-09-30
AGM

Annual General Meeting 2026

2026-07-15

Eutopos Pharma selected to join Quest for Health Accelerator

Strasbourg, France

2026-06-30
Financial

Audited annual consolidated financial report (year ended 31 Dec 2025)

2026-05-01
Clinical

Clinical trial interim report

2026-05-01

Quest for Health Accelerator negotiations / admission

Strasbourg, France

2026-04-01
Conference

HNWI Non-Deal Roadshow (Frankfurt, Hamburg, Munich, Vienna)

Germany & Austria

2026-04-01

Facts on Video with Lyndsay Malchuk

2026-03-01
Regulatory

OTC Markets filing (USA)

USA

2026-03-01
Regulatory

Quest for Health admission application

Strasbourg, France

2026-02-23
Conference

11th ILANIT / FISEB Conference

Eilat, Israel

2026-01-01
Clinical

First patient dosed in Phase 2B trial (high-proliferative AK)

2025-12-03
Conference

Virtual investor conference — 17th International Investment Forum (850 attendees)

2025-12-01
Clinical

Phase 2B trial initiation at CentroDerm (Germany)

Germany

2025-11-24
Regulatory

Prospectus publication

2025-11-24
Regulatory

Düsseldorf Stock Exchange application

2025-10-23
Conference

Basel Launch — Beyond the Needle Event

Basel, Switzerland

2025-03-04
Conference

First Pediatric Brain Tumor Research Meeting

2025-02-26
Conference

18th Annual European Life Sciences CEO Forum — Sachs Associates

Zurich, Switzerland

2025-02-24
Conference

Investor Roadshow — Frankfurt & Munich

Frankfurt & Munich, Germany

2025-01-23
Conference

Innovative Brain Cancer Meeting

Google Campus, Tel Aviv

2024-06-30
Financial

Annual Report 2024 publication

2024-02-28
Conference

17th Annual European Life Sciences CEO Forum — Sachs Associates

Zurich, Switzerland

2023-10-24
Conference

HTID 5 — HealthTech Innovation Days

Paris, France

2023-06-30
Financial

Annual Report 2023 publication

2022-10-13
Conference

HTID 4 — HealthTech Innovation Days

Paris, France

Financial Reports & Documents

Analyst Coverage

Coverage provided by Sphene Capital GmbH

Sphene Capital provides independent equity research coverage of Vidac Pharma. Research reports are available in the Documents section above under "Analyst Coverage".

Securities Disclaimer

Important Legal Notice — Geographic Restrictions

The documents and information on this page are NOT INTENDED FOR PERSONS RESIDING IN THE UNITED STATES OF AMERICA, nor for persons in Australia, Canada, Israel, Japan, New Zealand, or their respective territories and possessions.

These documents do not constitute an offer to sell securities or a solicitation of an offer to purchase securities in any jurisdiction where such offer or sale is not permitted. The public offer is limited to the Federal Republic of Germany only, conducted exclusively under German law.

Shares of Vidac Pharma Holdings PLC have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, US persons except pursuant to applicable exemptions.

The securities prospectus has been approved by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin).

This website and its content do not constitute investment advice. Past performance is not indicative of future results. Please read our full Disclaimer and Privacy Policy.